Roivant Sciences
Open
$30.46
Prev. Close
$30.46
High
$30.57
Low
$30.34
Market Snapshot
$21.76B
-72.6
-0.15
$50.41M
750
Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. The Company’s pipeline includes brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. The company also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.
Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. The Company’s pipeline includes brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. The company also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.
Recently from Cashu
Rubric Capital Invests in Seaport Entertainment Group: A Strategic Move for Roivant Sciences
Rubric Capital's Strategic Investment in Seaport Entertainment Group: A New Frontier in Real Estate and Entertainment Rubric Capital Management LP recently makes headlines with its acquisition of 276,…
Organon Acquires Dermavant from Roivant Sciences to Boost Women's Dermatological Health
Organon Enhances Women's Health Focus with Dermavant Acquisition Organon, a global healthcare company dedicated to advancing women's health, recently finalizes its acquisition of Dermavant Sciences Lt…
Organon Acquires Dermavant from Roivant Sciences to Enhance Dermatological Care
Organon's Strategic Acquisition of Dermavant: A New Era in Dermatological Care In a significant move aimed at bolstering its position in the dermatology sector, Organon (NYSE: OGN) has finalized the a…